- Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
-
Shimizu H, Fujii T, Hibiya S, Motobayashi M, Suzuki K, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2512107
- Intest Res.
- 2021 Jan;19(1):115-118.
- doi: 10.5217/ir.2020.00030
-
- CITED
-
- Close
- SHARE
-
- Close
- Pathogenesis of Inflammatory Bowel Diseases
-
Nagahori M, Nemoto Y, Watanabe M
- KMID: 1974725
- Intest Res.
- 2010 Jun;8(1):9-17.
- doi: 10.5217/ir.2010.8.1.9
Our understanding of IBD pathogenesis has been increasing rapidly. The genetically determined interplay between the commensal microbiota, intestinal epithelial cells, and the immune system has been appreciated deeply. The interplay... -
- CITED
-
- Close
- SHARE
-
- Close
- Tacrolimus for the Treatment of Ulcerative Colitis
-
Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2174466
- Intest Res.
- 2015 Jul;13(3):219-226.
- doi: 10.5217/ir.2015.13.3.219
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
-
Shimizu H, Aonuma Y, Hibiya S, Kawamoto A, Takenaka K, Fujii T, Saito E, Nagahori M, Ohtsuka K, Okamoto R
- KMID: 2558196
- Intest Res.
- 2024 Jul;22(3):369-377.
- doi: 10.5217/ir.2023.00194
Background/Aims: The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
-
Hisamatsu , Kunisaki R, Nakamura S, Tsujikawa , Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M, CERISIER Trial group
- KMID: 2417663
- Intest Res.
- 2018 Jul;16(3):494-498.
- doi: 10.5217/ir.2018.16.3.494
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
-
Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T
- KMID: 2521608
- Intest Res.
- 2021 Oct;19(4):448-460.
- doi: 10.5217/ir.2020.00026
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
-
Kobayashi , Hisamatsu , Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto , Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa , Sasaki M, Yokoyama K, Yoshimura , Watanabe K, Katafuchi , Watanabe M, Hibi T
- KMID: 2417669
- Intest Res.
- 2018 Apr;16(2):168-177.
- doi: 10.5217/ir.2018.16.2.168
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international... -
- CITED
-
- Close
- SHARE
-
- Close
